<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Eisai Co., Ltd. — News on 6ix</title>
<link>https://6ix.com/company/eisai-co-ltd</link>
<description>Latest news and press releases for Eisai Co., Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 10:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/eisai-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d62150beedb30cb6fc2afe.webp</url>
<title>Eisai Co., Ltd.</title>
<link>https://6ix.com/company/eisai-co-ltd</link>
</image>
<item>
<title>Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)</title>
<link>https://6ix.com/company/eisai-co-ltd/news/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination-treatments-for-certain-patients-with-advanced-renal-cell-carcinoma-rcc</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination-treatments-for-certain-patients-with-advanced-renal-cell-carcinoma-rcc</guid>
<pubDate>Tue, 21 Apr 2026 10:45:00 GMT</pubDate>
<description>RAHWAY, N.J. & NUTLEY, N.J., April 21, 2026--Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced RCC</description>
</item>
<item>
<title>Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting</title>
<link>https://6ix.com/company/eisai-co-ltd/news/eisai-to-present-the-latest-data-on-real-world-treatment-with-lecanemab-and-supporting-a-standardized-framework-for-treating-early-alzheimers-disease-at-the-78th-american-academy-of-neurologys-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/eisai-to-present-the-latest-data-on-real-world-treatment-with-lecanemab-and-supporting-a-standardized-framework-for-treating-early-alzheimers-disease-at-the-78th-american-academy-of-neurologys-annual-meeting</guid>
<pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
<description>Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 2026 American Academy of Neurology (AAN) Annual Meeting from April 18-22 in Chicago and online. The lecanemab data and additional research findings from Eisai's neurology portfolio will be featured in 14 presentations, including four oral presentations. Eisai will also h</description>
</item>
<item>
<title>Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency</title>
<link>https://6ix.com/company/eisai-co-ltd/news/eisai-and-nuvation-bio-announce-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-by-the-european-medicines-agency</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/eisai-and-nuvation-bio-announce-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-by-the-european-medicines-agency</guid>
<pubDate>Thu, 26 Mar 2026 20:05:00 GMT</pubDate>
<description>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., "Nuvation Bio"), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisat</description>
</item>
<item>
<title>New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress</title>
<link>https://6ix.com/company/eisai-co-ltd/news/new-data-on-long-term-real-world-treatment-with-lecanemab-presented-at-the-2026-adpdtm-congress</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/new-data-on-long-term-real-world-treatment-with-lecanemab-presented-at-the-2026-adpdtm-congress</guid>
<pubDate>Mon, 23 Mar 2026 07:54:00 GMT</pubDate>
<description>BioArctic's AB (publ) (STOCKHOLM: BIOA B ) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21. BioArctic also held an oral presentation on lecanemab and a poster presentation relating to exidavnemab.</description>
</item>
<item>
<title>Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026</title>
<link>https://6ix.com/company/eisai-co-ltd/news/results-from-real-world-long-term-treatment-persistence-with-leqembir-lecanemab-irmb-in-the-united-states-presented-at-adpdtm-2026</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/results-from-real-world-long-term-treatment-persistence-with-leqembir-lecanemab-irmb-in-the-united-states-presented-at-adpdtm-2026</guid>
<pubDate>Fri, 20 Mar 2026 16:05:00 GMT</pubDate>
<description>Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanem</description>
</item>
<item>
<title>Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress</title>
<link>https://6ix.com/company/eisai-co-ltd/news/latest-data-on-long-term-real-world-treatment-with-lecanemab-will-be-presented-at-the-adpdtm-2026-congress</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/latest-data-on-long-term-real-world-treatment-with-lecanemab-will-be-presented-at-the-adpdtm-2026-congress</guid>
<pubDate>Wed, 11 Mar 2026 07:28:00 GMT</pubDate>
<description>BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, and online. In addition, BioArctic will have an oral presentation on lecanemab and a poster presentation relating to exidavnemab at the conference.</description>
</item>
<item>
<title>Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting</title>
<link>https://6ix.com/company/eisai-co-ltd/news/eisai-to-present-the-latest-data-on-long-term-real-world-treatment-with-lecanemab-at-the-adpdtm-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/eisai-to-present-the-latest-data-on-long-term-real-world-treatment-with-lecanemab-at-the-adpdtm-2026-annual-meeting</guid>
<pubDate>Tue, 10 Mar 2026 23:30:00 GMT</pubDate>
<description>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab data and additional resea</description>
</item>
<item>
<title>WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)</title>
<link>https://6ix.com/company/eisai-co-ltd/news/weliregr-belzutifan-plus-lenvimar-lenvatinib-reduced-the-risk-of-disease-progression-or-death-by-30percent-compared-to-cabozantinib-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma-rcc-1</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/weliregr-belzutifan-plus-lenvimar-lenvatinib-reduced-the-risk-of-disease-progression-or-death-by-30percent-compared-to-cabozantinib-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma-rcc-1</guid>
<pubDate>Sat, 28 Feb 2026 15:00:00 GMT</pubDate>
<description>RAHWAY, N.J. & NUTLEY, N.J., February 28, 2026--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients</description>
</item>
<item>
<title>Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment</title>
<link>https://6ix.com/company/eisai-co-ltd/news/eisai-maintains-commitment-to-people-living-with-early-alzheimers-disease-despite-cda-amc-draft-recommendation-patients-deserve-access-to-effective-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/eisai-maintains-commitment-to-people-living-with-early-alzheimers-disease-despite-cda-amc-draft-recommendation-patients-deserve-access-to-effective-treatment</guid>
<pubDate>Thu, 19 Feb 2026 15:44:00 GMT</pubDate>
<description>Eisai Limited ("Eisai") and Biogen Canada Inc. are disappointed by and disagree with Canada's Drug Agency (CDA-AMC) that the Agency will not recommend LEQEMBI® for public reimbursement in Canada. This draft recommendation was made despite clinical data and evidence that treatment with LEQEMBI® slows both disease progression and functional decline in patients with early Alzheimer's Disease (AD).1,2</description>
</item>
<item>
<title>BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China</title>
<link>https://6ix.com/company/eisai-co-ltd/news/bla-for-subcutaneous-formulation-of-leqembir-designated-for-priority-review-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/bla-for-subcutaneous-formulation-of-leqembir-designated-for-priority-review-in-china</guid>
<pubDate>Mon, 09 Feb 2026 06:07:00 GMT</pubDate>
<description>BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI), has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The BLA for the subcutaneous formulation was accepted for review by the NMPA in January 2026.</description>
</item>
<item>
<title>Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China</title>
<link>https://6ix.com/company/eisai-co-ltd/news/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-designated-for-priority-review-in-china-1</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-designated-for-priority-review-in-china-1</guid>
<pubDate>Mon, 09 Feb 2026 02:00:00 GMT</pubDate>
<description>TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, whi</description>
</item>
<item>
<title>Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025</title>
<link>https://6ix.com/company/eisai-co-ltd/news/sales-of-leqembir-totaled-207-billion-yen-in-the-fourth-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/sales-of-leqembir-totaled-207-billion-yen-in-the-fourth-quarter-2025</guid>
<pubDate>Fri, 06 Feb 2026 11:23:00 GMT</pubDate>
<description>BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024.</description>
</item>
<item>
<title>Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan</title>
<link>https://6ix.com/company/eisai-co-ltd/news/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan-1</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan-1</guid>
<pubDate>Thu, 05 Feb 2026 11:44:00 GMT</pubDate>
<description>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan.</description>
</item>
<item>
<title>Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai</title>
<link>https://6ix.com/company/eisai-co-ltd/news/total-investment-of-approx-usd-88-million-in-malaria-tuberculosis-and-ntd-randd-projects-with-partners-including-mahidol-university-barcelona-institute-for-global-health-and-eisai</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/total-investment-of-approx-usd-88-million-in-malaria-tuberculosis-and-ntd-randd-projects-with-partners-including-mahidol-university-barcelona-institute-for-global-health-and-eisai</guid>
<pubDate>Tue, 03 Feb 2026 01:00:00 GMT</pubDate>
<description>The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projects for the development of drugs, diagnostics and vaccines for malaria, tuberculosis (TB), and neglected tropical diseases (NTDs).2</description>
</item>
<item>
<title>Eisai: Canada's Drug Agency Recommendation Denies Canadians Safer Insomnia Treatments</title>
<link>https://6ix.com/company/eisai-co-ltd/news/eisai-canadas-drug-agency-recommendation-denies-canadians-safer-insomnia-treatments</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/eisai-canadas-drug-agency-recommendation-denies-canadians-safer-insomnia-treatments</guid>
<pubDate>Thu, 29 Jan 2026 17:30:00 GMT</pubDate>
<description>Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, is deeply disappointed by Canada's Drug Agency (CDA-AMC)'s recommendation to not publicly reimburse DAYVIGO (lemborexant) for the treatment of chronic insomnia disorder (CID), characterized by difficulties with sleep onset and/or maintenance occurring at least three nights per week for a minimum of three months. This is the second time CDA-AMC has made this recommendation. In th</description>
</item>
<item>
<title>Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)</title>
<link>https://6ix.com/company/eisai-co-ltd/news/eisai-submits-marketing-authorisation-variation-to-ema-for-intravenous-maintenance-dosing-every-four-weeks-with-leqembir-lecanemab</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/eisai-submits-marketing-authorisation-variation-to-ema-for-intravenous-maintenance-dosing-every-four-weeks-with-leqembir-lecanemab</guid>
<pubDate>Mon, 26 Jan 2026 21:13:00 GMT</pubDate>
<description>BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) for a once every four weeks intravenous (IV) infusion maintenance dosing for lecanemab.</description>
</item>
<item>
<title>Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA</title>
<link>https://6ix.com/company/eisai-co-ltd/news/leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-regarding-subcutaneous-starting-dose-granted-priority-review-by-the-us-fda</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-regarding-subcutaneous-starting-dose-granted-priority-review-by-the-us-fda</guid>
<pubDate>Mon, 26 Jan 2026 02:48:00 GMT</pubDate>
<description>BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the U.S. Food and Drug Administration (FDA). Leqembi is indicated for the treatment of Alzheimer's disease in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early Alzheimer's disease). A Prescription</description>
</item>
<item>
<title>FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review</title>
<link>https://6ix.com/company/eisai-co-ltd/news/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-priority-review-2</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-priority-review-2</guid>
<pubDate>Sun, 25 Jan 2026 23:30:00 GMT</pubDate>
<description>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. LEQEMBI is indicated for the treatment of</description>
</item>
<item>
<title>Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan</title>
<link>https://6ix.com/company/eisai-co-ltd/news/nuvation-bio-and-eisai-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-us-china-and-japan</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/nuvation-bio-and-eisai-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-us-china-and-japan</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>NEW YORK & TOKYO, January 12, 2026--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., "Nuvation Bio"), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, today announced an exclusive license and collaboration agree</description>
</item>
<item>
<title>EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan</title>
<link>https://6ix.com/company/eisai-co-ltd/news/ea-pharma-a-subsidiary-of-eisai-announces-the-initiation-of-its-phase-iii-clinical-trial-with-evenamide-a-novel-treatment-for-schizophrenia-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/eisai-co-ltd/news/ea-pharma-a-subsidiary-of-eisai-announces-the-initiation-of-its-phase-iii-clinical-trial-with-evenamide-a-novel-treatment-for-schizophrenia-in-japan</guid>
<pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
<description>MILAN & MORRISTOWN, N.J., January 07, 2026--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.</description>
</item>
</channel>
</rss>